# DAXX

## Overview
DAXX, or Death Domain Associated Protein, is a gene that encodes a multifunctional protein involved in various cellular processes, including transcriptional repression, apoptosis regulation, and chromatin remodeling. The DAXX protein is characterized as a histone chaperone, facilitating the deposition of histone variant H3.3 into chromatin, and is known for its interactions with a wide array of proteins, such as ATRX and PML, which are crucial for its role in maintaining genomic stability and regulating gene expression (Michaelson2003RNAi; Ishov2004Heterochromatin). DAXX is predominantly localized in the nucleus, where it associates with promyelocytic leukemia nuclear bodies and heterochromatin, contributing to the repression of transcription through its interactions with transcription factors and histone deacetylases (Li2000Sequestration). Clinically, mutations in the DAXX gene have been implicated in various cancers, including pancreatic neuroendocrine tumors and neuroblastomas, where they are associated with poor prognosis and aggressive disease progression (Pipinikas2015Epigenetic; Kurihara2014Clinical).

## Structure
The DAXX protein is characterized by a distinct structural organization, featuring several domains that contribute to its multifunctional roles. The N-terminal region contains a well-defined helical bundle domain, known as the DAXX Helical Bundle (DHB) domain, which forms a left-handed four-helix bundle with a crossover helix (H3) (EscobarCabrera2010Structural). This domain is crucial for mediating protein interactions, including those with Rassf1C, Mdm2, and p53, and is involved in transcription regulation and apoptosis (EscobarCabrera2010Structural).

The DHB domain shares structural similarities with the TFIIS domain I, featuring a unique arrangement where helices H1 and H4, and H2 and H5, are parallel due to the crossover of helix H3 (EscobarCabrera2010Structural). The C-terminal region of DAXX is intrinsically disordered and rich in polar residues, serving as sites for regulatory post-translational modifications such as sumoylation and phosphorylation (EscobarCabrera2010Structural).

DAXX also contains a histone-binding domain (HBD) in the middle, which is responsible for its histone chaperone activity, specifically recognizing and binding the histone H3.3-H4 dimer (Li2017Structural). The protein's ability to interact with sumoylated transcription factors and histone deacetylases is noted, although specific post-translational modifications and splice variant isoforms are not detailed in the provided context (EscobarCabrera2010Structural).

## Function
DAXX is a multifunctional protein involved in transcriptional repression, apoptosis regulation, and chromatin remodeling. In healthy human cells, DAXX primarily localizes to the nucleus, associating with promyelocytic leukemia oncogenic domains (PODs or ND10s) and heterochromatin. It interacts with proteins such as ATRX and PML, playing a crucial role in maintaining genomic stability and regulating gene expression (Michaelson2003RNAi; Ishov2004Heterochromatin).

DAXX functions as a transcriptional repressor by interacting with DNA-binding transcription factors and recruiting histone deacetylases, which leads to histone deacetylation and transcriptional repression (Li2000Sequestration). It is also involved in the reestablishment of epigenetic markers, such as deacetylated histones and methylated DNA, which are essential for maintaining the repressed state of certain genomic regions after replication (Ishov2004Heterochromatin).

DAXX plays a protective role against apoptosis, acting as an anti-apoptotic factor in various cellular contexts. It can inhibit apoptosis pathways, such as those mediated by CD43, and its depletion leads to increased apoptosis in certain cell types (Michaelson2003RNAi). Additionally, DAXX is involved in chromatin dynamics, particularly during the cell cycle, where it accumulates at heterochromatin during late S-phase, suggesting a role in post-replication chromatin modification (Ishov2004Heterochromatin).

## Clinical Significance
Mutations and alterations in the DAXX gene are implicated in several diseases, particularly various forms of cancer. In pancreatic neuroendocrine tumors (PNETs), DAXX mutations are associated with epigenetic dysregulation, poorer prognosis, and advanced tumor stages. These mutations often lead to alternative lengthening of telomeres (ALT) and chromosomal instability, contributing to tumor progression and metastasis (Pipinikas2015Epigenetic). Studies have shown that DAXX mutations in PNETs correlate with poor progression-free and overall survival, highlighting their role in aggressive tumor behavior (Wang2021Prognostic; Yuan2014KRAS).

DAXX mutations are also significant in neuroblastomas, where they are linked to elongated telomeres and poor clinical outcomes. These mutations are associated with chemoresistance and late recurrence, particularly in cases detected after 18 months of age (Kurihara2014Clinical). In neuroendocrine tumors treated with embolization, DAXX mutations predict shorter hepatic progression-free survival, indicating a more aggressive disease course (Ziv2018DAXX). The presence of DAXX mutations in these cancers suggests their potential as biomarkers for prognosis and treatment response.

## Interactions
DAXX is involved in numerous physical interactions with other proteins, playing a significant role in transcriptional regulation and apoptosis. It interacts with the promyelocytic leukemia protein (PML), which is crucial for its localization in PML nuclear bodies (Ishov1999Pml; Li2000Sequestration). DAXX also interacts with heat-shock protein HSP27 and Parkinson's disease protein DJ-1, which inhibit its pro-apoptotic function (Yeung2007Daxx). 

DAXX acts as a corepressor in transcription by interacting with several transcription factors, including Pax3/5, ETS1, p53, Smad4, STAT3, and nuclear receptors for androgen and glucocorticoid (GR) (Yeung2007Daxx; Li2000EAP1Daxx). It also interacts with transcriptional coactivators like CBP and Skip/NCoA62, and corepressors such as histone deacetylases (HDACs) and DNA methyltransferase 1-associated protein DMAP1 (Muromoto2004Physical; Li2000Sequestration). 

DAXX forms a complex with DMAP1 and DNMT1 in the nucleus, which may have implications for transcriptional repression (Muromoto2004Physical). It also interacts with TSG101, enhancing DAXX-mediated repression of glucocorticoid receptor transcriptional activity (Muromoto2004Physicala). DAXX's interactions with these proteins suggest its role in modulating chromatin structure and gene expression.


## References


[1. (Muromoto2004Physicala) Ryuta Muromoto, Kenji Sugiyama, Tetsuya Yamamoto, Kenji Oritani, Kazuya Shimoda, and Tadashi Matsuda. Physical and functional interactions between daxx and tsg101. Biochemical and Biophysical Research Communications, 316(3):827–833, April 2004. URL: http://dx.doi.org/10.1016/j.bbrc.2004.02.126, doi:10.1016/j.bbrc.2004.02.126. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2004.02.126)

[2. (Ishov1999Pml) Alexander M. Ishov, Alexey G. Sotnikov, Dmitri Negorev, Olga V. Vladimirova, Norma Neff, Tetsu Kamitani, Edward T.H. Yeh, Jerome F. Strauss, and Gerd G. Maul. Pml is critical for nd10 formation and recruits the pml-interacting protein daxx to this nuclear structure when modified by sumo-1. The Journal of Cell Biology, 147(2):221–234, October 1999. URL: http://dx.doi.org/10.1083/JCB.147.2.221, doi:10.1083/jcb.147.2.221. This article has 1021 citations.](https://doi.org/10.1083/JCB.147.2.221)

[3. (Wang2021Prognostic) Fei Wang, Xiaowu Xu, Zeng Ye, Yi Qin, Xianjun Yu, and Shunrong Ji. Prognostic significance of altered atrx/daxx gene in pancreatic neuroendocrine tumors: a meta-analysis. Frontiers in Endocrinology, June 2021. URL: http://dx.doi.org/10.3389/fendo.2021.691557, doi:10.3389/fendo.2021.691557. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2021.691557)

[4. (Kurihara2014Clinical) Sho Kurihara, Eiso Hiyama, Yoshiyuki Onitake, Emi Yamaoka, and Keiko Hiyama. Clinical features of atrx or daxx mutated neuroblastoma. Journal of Pediatric Surgery, 49(12):1835–1838, December 2014. URL: http://dx.doi.org/10.1016/j.jpedsurg.2014.09.029, doi:10.1016/j.jpedsurg.2014.09.029. This article has 47 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jpedsurg.2014.09.029)

[5. (Ishov2004Heterochromatin) Alexander M. Ishov, Olga V. Vladimirova, and Gerd G. Maul. Heterochromatin and nd10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor daxx and swi/snf protein atrx. Journal of Cell Science, 117(17):3807–3820, August 2004. URL: http://dx.doi.org/10.1242/jcs.01230, doi:10.1242/jcs.01230. This article has 123 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.01230)

[6. (Yuan2014KRAS) Fei Yuan, Min Shi, Jun Ji, Hailong Shi, Chenfei Zhou, Yingyan Yu, Bingya Liu, Zhenggang Zhu, and Jun Zhang. Kras and daxx/atrx gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in chinese patients with pancreatic neuroendocrine tumors. International Journal of Biological Sciences, 10(9):957–965, 2014. URL: http://dx.doi.org/10.7150/ijbs.9773, doi:10.7150/ijbs.9773. This article has 54 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/ijbs.9773)

[7. (Li2000Sequestration) Hui Li, Christopher Leo, Jiang Zhu, Xiaoyang Wu, Jennifer O’Neil, Eun-Ju Park, and J. Don Chen. Sequestration and inhibition of daxx-mediated transcriptional repression by pml. Molecular and Cellular Biology, 20(5):1784–1796, March 2000. URL: http://dx.doi.org/10.1128/mcb.20.5.1784-1796.2000, doi:10.1128/mcb.20.5.1784-1796.2000. This article has 297 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.20.5.1784-1796.2000)

[8. (Yeung2007Daxx) Percy Luk Yeung, Liuh‐Yow Chen, Shih‐Chieh Tsai, Aihua Zhang, and J. Don Chen. Daxx contains two nuclear localization signals and interacts with importin α3. Journal of Cellular Biochemistry, 103(2):456–470, July 2007. URL: http://dx.doi.org/10.1002/jcb.21408, doi:10.1002/jcb.21408. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.21408)

[9. (Ziv2018DAXX) Etay Ziv, Samuel L. Rice, John Filtes, Hooman Yarmohammadi, F. Edward Boas, Joseph P. Erinjeri, Elena Nadia Petre, Lynn A. Brody, Karen T. Brown, Anne M. Covey, George I. Getrajdman, Majid Maybody, Nitya Raj, Constantinos T. Sofocleous, Stephen B. Solomon, and Diane Reidy-Lagunes. Daxx mutation status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression. Journal of Vascular and Interventional Radiology, 29(11):1519–1526, November 2018. URL: http://dx.doi.org/10.1016/j.jvir.2018.05.023, doi:10.1016/j.jvir.2018.05.023. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jvir.2018.05.023)

[10. (Li2000EAP1Daxx) Runzhao Li, Huiping Pei, Dennis K Watson, and Takis S Papas. Eap1/daxx interacts with ets1 and represses transcriptional activation of ets1 target genes. Oncogene, 19(6):745–753, February 2000. URL: http://dx.doi.org/10.1038/sj.onc.1203385, doi:10.1038/sj.onc.1203385. This article has 151 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1203385)

[11. (EscobarCabrera2010Structural) Eric Escobar-Cabrera, Desmond K.W. Lau, Serena Giovinazzi, Alexander M. Ishov, and Lawrence P. McIntosh. Structural characterization of the daxx n-terminal helical bundle domain and its complex with rassf1c. Structure, 18(12):1642–1653, December 2010. URL: http://dx.doi.org/10.1016/j.str.2010.09.016, doi:10.1016/j.str.2010.09.016. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.str.2010.09.016)

[12. (Michaelson2003RNAi) Jennifer S. Michaelson and Philip Leder. Rnai reveals anti-apoptotic and transcriptionally repressive activities of daxx. Journal of Cell Science, 116(2):345–352, January 2003. URL: http://dx.doi.org/10.1242/jcs.00234, doi:10.1242/jcs.00234. This article has 108 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.00234)

[13. (Li2017Structural) Zhuang Li, Dan Zhao, Bin Xiang, and Haitao Li. Structural and biochemical characterization of daxx-atrx interaction. Protein &amp; Cell, 8(10):762–766, September 2017. URL: http://dx.doi.org/10.1007/s13238-017-0463-x, doi:10.1007/s13238-017-0463-x. This article has 8 citations.](https://doi.org/10.1007/s13238-017-0463-x)

[14. (Muromoto2004Physical) Ryuta Muromoto, Kenji Sugiyama, Akie Takachi, Seiyu Imoto, Noriko Sato, Tetsuya Yamamoto, Kenji Oritani, Kazuya Shimoda, and Tadashi Matsuda. Physical and functional interactions between daxx and dna methyltransferase 1-associated protein, dmap1. The Journal of Immunology, 172(5):2985–2993, March 2004. URL: http://dx.doi.org/10.4049/jimmunol.172.5.2985, doi:10.4049/jimmunol.172.5.2985. This article has 73 citations.](https://doi.org/10.4049/jimmunol.172.5.2985)

[15. (Pipinikas2015Epigenetic) Christodoulos P Pipinikas, Harpreet Dibra, Anna Karpathakis, Andrew Feber, Marco Novelli, Dahmane Oukrif, Guiseppe Fusai, Roberto Valente, Martyn Caplin, Tim Meyer, Andrew Teschendorff, Christopher Bell, Tiffany J Morris, Paolo Salomoni, Tu-Vinh Luong, Brian Davidson, Stephan Beck, and Christina Thirlwell. Epigenetic dysregulation and poorer prognosis in daxx-deficient pancreatic neuroendocrine tumours. Endocrine-Related Cancer, 22(3):L13–L18, April 2015. URL: http://dx.doi.org/10.1530/erc-15-0108, doi:10.1530/erc-15-0108. This article has 49 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1530/erc-15-0108)